Psychosis News and Research RSS Feed - Psychosis News and Research

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''
Coordinated specialty care more cost-effective for young people with first episode psychosis

Coordinated specialty care more cost-effective for young people with first episode psychosis

New analysis from a mental health care study shows that "coordinated specialty care" (CSC) for young people with first episode psychosis is more cost-effective than typical community care. Cost-effectiveness analysis in health care is a way to compare the costs and benefits of two or more treatment options. [More]
Frequent traumatic experiences throughout infancy increase risk of psychosis during adulthood

Frequent traumatic experiences throughout infancy increase risk of psychosis during adulthood

A research carried out with participation of the University of Granada proves that suffering repeated traumatic experiences throughout infancy and adolescence multiplies by 7 the risk of suffering psychosis during adulthood. [More]
Research offers novel insights into root causes of schizophrenia

Research offers novel insights into root causes of schizophrenia

Schizophrenia is a mysterious and devastating disorder that afflicts one percent of the adult population worldwide. Its symptoms — hallucinations, emotional withdrawal, and cognitive impairment — are chronic and typically emerge just as individuals are entering adulthood. Today's medications treat just one of these symptoms (psychosis); treatments for the underlying disease and its many other symptoms have been hard to develop, because no one really understands what causes the disorder. [More]
Citalopram of limited use for dementia-associated agitation

Citalopram of limited use for dementia-associated agitation

The use of citalopram for the treatment of agitation in Alzheimer’s disease may be limited to a small group of people with moderate agitation and low levels of cognitive impairment, study findings suggest. [More]
Diseases that cause skin-related problems can also trigger serious neurological conditions

Diseases that cause skin-related problems can also trigger serious neurological conditions

Diseases such as lupus that cause rashes and other skin problems also can trigger migraine headaches, strokes and other serious neurological conditions, according to an article by Loyola University Medical Center physicians. [More]
Gene variant linked to psychotic symptoms, cognitive impairment in people with bipolar disorder identified

Gene variant linked to psychotic symptoms, cognitive impairment in people with bipolar disorder identified

Researchers at Karolinska Institutet, and the Sahlgrenska Academy at Gothenburg University in Sweden have identified a gene variant linked to psychotic symptoms and cognitive impairment in people with bipolar disorder. The study, which is published in the journal Molecular Psychiatry, describes a possible mechanism for how the gene variant produces clinical symptoms by affecting levels of specific proteins in the brain. [More]
LSD reduces connectivity within human brain networks

LSD reduces connectivity within human brain networks

LSD is known to cause changes in consciousness, including "ego-dissolution", or a loss of the sense of self. Despite a detailed knowledge of the action of LSD at specific serotonin receptors, it has not been understood how this these pharmacological effects can translate into such a profound effect on consciousness. [More]
Biotypes can identify distinct subgroups of psychosis

Biotypes can identify distinct subgroups of psychosis

Three biomarker-based categories, called biotypes, outperformed traditional diagnoses, such as schizophrenia and bipolar disorder with psychosis, in sorting psychosis cases into distinct subgroups on the basis of brain biology, report researchers funded by the National Institutes of Health. [More]
Groundbreaking study establishes empirical biomarkers to aid in diagnosis, treatment of psychosis

Groundbreaking study establishes empirical biomarkers to aid in diagnosis, treatment of psychosis

In a groundbreaking study led by UT Southwestern Medical Center, a comprehensive set of empirical biomarkers has been established to aid in diagnosis and treatment of psychosis. [More]
UGA researchers identify biological markers for mental disorders

UGA researchers identify biological markers for mental disorders

A team of researchers led by faculty at the University of Georgia has identified a number of biological markers that make it possible to classify mental disorders with greater precision. Their findings, published today in the American Journal of Psychiatry, may one day lead to improved diagnostics and treatments for those suffering from mental illness. [More]
New study reveals effect of cannabis potency on brain structure

New study reveals effect of cannabis potency on brain structure

Smoking high potency 'skunk-like' cannabis can damage a crucial part of the brain responsible for communication between the two brain hemispheres, according to a new study by scientists from King's College London and Sapienza University of Rome. [More]
UNC study reveals how specific schizophrenia symptoms linked to distinct brain circuits

UNC study reveals how specific schizophrenia symptoms linked to distinct brain circuits

Schizophrenia, a severe mental disorder affecting about one in 100 people, is notoriously difficult to diagnose and treat, in large part because it manifests differently in different people. A new study published today in Molecular Neuropsychiatry helps explain why. [More]
Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo. [More]

People with psychosis and addiction disorder may respond better to disorder-specific treatment

People with psychosis often develop an addiction disorder: almost one in two patients with schizophrenia are affected once during their lifetime. Patients with a dual diagnosis mostly have a poorer prognosis, and their disorder often becomes chronic. [More]
Team-based, coordinated specialty care approach produces better outcomes for people with first episode psychosis

Team-based, coordinated specialty care approach produces better outcomes for people with first episode psychosis

New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin. [More]
Long-term lithium exposure does not increase renal dysfunction risk

Long-term lithium exposure does not increase renal dysfunction risk

Stable lithium maintenance therapy does not increase the risk of renal dysfunction in patients with bipolar affective disorder, findings from a population-based study suggest. [More]
New analysis finds illogical thoughts as most predictive of schizophrenia risk

New analysis finds illogical thoughts as most predictive of schizophrenia risk

Despite decades of study, schizophrenia has remained stubbornly difficult to diagnose in its earliest stage - between the appearance of symptoms and the development of the disorder. Now, a new analysis led by researchers at the UNC School of Medicine and the Renaissance Computing Institute identified illogical thoughts as most predictive of schizophrenia risk. [More]
Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks. [More]
Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults. [More]
Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

The Brain & Behavior Research Foundation will honor nine scientists with its 2015 Outstanding Achievement Prizes for their work in schizophrenia, mood disorders, child and adolescent psychiatry, and cognitive neuroscience. [More]
Advertisement
Advertisement